NeoGenomics, Inc. Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs
NeoGenomics, Inc. (NEO) had Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs of $0 as of 2022-12-31, per its 10-K filed 2023-02-24.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts · last filed 2023-02-24
- 2022-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $0.00.
- 2021-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $1.00K.
- 2020-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $6.64M.
- 2019-12-31: Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs $0.00.
| Period end | Deferred Tax Liabilities, Deferred Expense, Debt Issuance Costs |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-24 |
| 2021-12-31 | $1.00K 10-K · filed 2023-02-24 |
| 2020-12-31 | $6.64M 10-K · filed 2022-02-25 |
| 2019-12-31 | $0.00 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |